Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2B | P29275 | 9/20 | 0.89 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.66 |
| ▸ | LMNA | P02545 | 2/20 | 0.62 |
| ▸ | MEN1 | O00255 | 1/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.62 |
| ▸ | MAPT | P10636 | 1/20 | 0.58 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.57 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.57 |
| ▸ | PDE4A | P27815 | 1/20 | 0.56 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.56 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.56 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Acefylline SCHEMBL18191994 | 0.94 | ADORA2B (1.00) | ADORA2BSMN1; SMN2LMNAMEN1KMT2A | |
| Acefylline SCHEMBL308514 | 0.94 | ADORA2B (1.00) | ADORA2BSMN1; SMN2LMNAMEN1KMT2A | |
| Acefylline SCHEMBL8402147 | 0.93 | ADORA2B (0.97) | ADORA2BSMN1; SMN2LMNAMEN1KMT2A | |
| Acefylline SCHEMBL356114 | 0.87 | ADORA2B (0.85) | ADORA2BSMN1; SMN2LMNAMEN1KMT2A | |
| Acefylline SCHEMBL5493561 | 0.87 | ADORA2B (0.85) | ADORA2BSMN1; SMN2LMNAMEN1KMT2A | |
| Acefylline SCHEMBL17204841 | 0.86 | ADORA2B (0.84) | ADORA2BSMN1; SMN2LMNAMEN1KMT2A | |
| SCHEMBL17163939 | 0.83 | ADORA2B (0.78) | ADORA2BSMN1; SMN2LMNAMEN1KMT2A | |
| SCHEMBL11531219 | 0.83 | ADORA2B (0.78) | ADORA2BSMN1; SMN2LMNAMEN1KMT2A | |
| SCHEMBL10178114 | 0.83 | ADORA2B (0.73) | ADORA2BLMNAMAPTPDE4APDE4B | |
| SCHEMBL10178116 | 0.83 | PDE4A (0.81) | ADORA2BPDE4APDE4BPDE4CPDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 191 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2821056-A1 | Cosmetic composition, formulation gel-cream and its use | EMS S.A. (BR) | 2015-01-07 | — | — | EP | claimed |
| US-20150005255-A1 | COSMETIC COMPOSITION, FORMULATION IN GEL-CREAM AND ITS USE | EMS S.A. (BR) | 2015-01-01 | — | — | US | claimed |
| US-20240237643-A1 | COMPOSITIONS WITH VIRUCIDAL AND/OR ANTIVIRAL ACTIVITY | SYMRISE AG (DE) | 2024-07-18 | — | — | US | disclosed |
| US-20240216248-A1 | MICROBIAL GLYCOLIPIDS | ANALYTICON DISCOVERY GMBH (DE) | 2024-07-04 | — | — | US | disclosed |
| EP-4387587-A1 | COMPOSITIONS | Symrise AG (DE) | 2024-06-26 | — | — | EP | disclosed |
| US-20240173227-A1 | A FRAGRANCE MIXTURE CONTAINING ISOCITRONELLOL | SYMRISE AG (DE) | 2024-05-30 | — | — | US | disclosed |
| WO-2024110515-A1 | AN ACTIVE COMPOSITION COMPRISING RETINOL | SYMRISE AG (DE) | 2024-05-30 | — | — | WO | disclosed |
| WO-2024110023-A1 | AN ACTIVE COMPOSITION COMPRISING RETINOL | SYMRISE AG (DE) | 2024-05-30 | — | — | WO | disclosed |
| WO-2024104625-A1 | A BLEND OF EMOLLIENTS | SYMRISE AG (DE) | 2024-05-23 | — | — | WO | disclosed |
| WO-2024104546-A1 | A BLEND OF EMOLLIENTS | SYMRISE AG (DE) | 2024-05-23 | — | — | WO | disclosed |
| US-20240122816-A1 | ARTICLES FOR INDIRECT TRANSFER OF COSMETIC ACTIVES TO SKIN | SYMRISE AG (DE) | 2024-04-18 | — | — | US | disclosed |
| US-20060205904-A1 | Oil gels of controlled distribution block copolymers and ester oils | UBS AG, STAMFORD BRANCH, AS COLLATERAL AGENT | 2006-09-14 | — | — | US | disclosed |
| US-20060205849-A1 | Oil gels of controlled distribution block copolymers and ester oils | KRATON POLYMERS U.S. LLC | 2006-09-14 | — | — | US | disclosed |
| EP-1141111-B1 | GEL COMPOSITIONS | PENRECO (US) | 2005-08-03 | — | — | EP | disclosed |
| US-6881776-B2 | Gel compositions | PENRECO (US) | 2005-04-19 | — | — | US | disclosed |
| US-20050004274-A1 | Gel compositions | HEALY LIN LU (US) | 2005-01-06 | — | — | US | disclosed |
| EP-1256336-A2 | Two-phase gel composition | Penreco (US) | 2002-11-13 | — | — | EP | disclosed |
| US-20020055562-A1 | Gel compositions | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2002-05-09 | — | — | US | disclosed |
| EP-1141111-A1 | GEL COMPOSITIONS | Penreco (US) | 2001-10-10 | — | — | EP | disclosed |
| WO-2000026285-A1 | GEL COMPOSITIONS | PENRECO (US) | 2000-05-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240216248-A1 | MICROBIAL GLYCOLIPIDS | UGCG, SGMS1, GPR119 | ADORA2B 3644/4885SMN1; SMN2 4097/4885LMNA 4411/4885 |
| US-20240122816-A1 | ARTICLES FOR INDIRECT TRANSFER OF COSMETIC ACTIVES TO SKIN | CUTA, POLR1C, SLC16A7 | ADORA2B 1235/4885SMN1; SMN2 3272/4885LMNA 2718/4885 |
| US-20240237643-A1 | COMPOSITIONS WITH VIRUCIDAL AND/OR ANTIVIRAL ACTIVITY | ZC3HAV1, SAMHD1, ZC3HAV1L | ADORA2B 2935/4885SMN1; SMN2 3187/4885LMNA 2563/4885 |
| US-20240173227-A1 | A FRAGRANCE MIXTURE CONTAINING ISOCITRONELLOL | IPO5, OR51E2, FDFT1 | ADORA2B 4804/4885SMN1; SMN2 4173/4885LMNA 3949/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.